These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22139081)

  • 61. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High snail expression predicts a poor prognosis in breast invasive ductal carcinoma patients with HER2/EGFR-positive subtypes.
    Chang HY; Tseng YK; Chen YC; Shu CW; Lin MI; Liou HH; Fu TY; Lin YC; Ger LP; Yeh MH; Liu PF
    Surg Oncol; 2018 Jun; 27(2):314-320. PubMed ID: 29937187
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer.
    Schoppmann SF; Tamandl D; Roberts L; Jomrich G; Schoppmann A; Zwrtek R; Dubsky P; Gnant M; Jakesz R; Birner P
    Ann Oncol; 2010 May; 21(5):955-60. PubMed ID: 19940005
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185erbB-2.
    Ram TG; Dilts CA; Dziubinski ML; Pierce LJ; Ethier SP
    Mol Carcinog; 1996 Mar; 15(3):227-38. PubMed ID: 8597535
    [TBL] [Abstract][Full Text] [Related]  

  • 65. TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness.
    Sundqvist A; Vasilaki E; Voytyuk O; Bai Y; Morikawa M; Moustakas A; Miyazono K; Heldin CH; Ten Dijke P; van Dam H
    Oncogene; 2020 May; 39(22):4436-4449. PubMed ID: 32350443
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility.
    Brandt B; Kemming D; Packeisen J; Simon R; Helms M; Feldmann U; Matuschek A; Kersting C; Hinrichs B; Bidart JM; Bellet D; Bartkowiak K; Dankbar N; Dittmar T; Sauter G; Boecker W; Buerger H
    Endocr Relat Cancer; 2005 Dec; 12(4):823-37. PubMed ID: 16322324
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification.
    Tang Y; Mackey J; Lai R; Ghosh S; Santos C; Graham K; Damaraju S; Pasdar M; Li L
    J Proteomics; 2013 Oct; 91():200-9. PubMed ID: 23851309
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Salivary Her2/neu Levels in Differentiation of Oral Premalignant Disorders and Oral Squamous Cell Carcinomas.
    Varun C; Dineshkumar T; Jayant VS; Rameshkumar A; Rajkumar K; Rajashree P; Mathew J; Arunvignesh RK
    Asian Pac J Cancer Prev; 2015; 16(14):5773-7. PubMed ID: 26320450
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
    Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
    J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.
    Nava M; Dutta P; Zemke NR; Farias-Eisner R; Vadgama JV; Wu Y
    BMC Med Genomics; 2019 Feb; 12(1):32. PubMed ID: 30736768
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
    Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
    Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
    Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
    Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration.
    Wolf-Yadlin A; Kumar N; Zhang Y; Hautaniemi S; Zaman M; Kim HD; Grantcharova V; Lauffenburger DA; White FM
    Mol Syst Biol; 2006; 2():54. PubMed ID: 17016520
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of HER2/neu in tumor progression and therapy.
    Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
    Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Expression of wild-type estrogen receptor beta protein in human breast cancer: specific correlation with HER2/neu overexpression.
    Umekita Y; Souda M; Ohi Y; Sagara Y; Rai Y; Takahama T; Yoshida H
    Pathol Int; 2006 Aug; 56(8):423-7. PubMed ID: 16872435
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.